Skip to main content
Evidence Snapshot

Histone deacetylase 11

CHEMBL3310 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:45Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3310
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Histone deacetylase 11 as ChEMBL target CHEMBL3310, mapped to UniProt Q96DB2. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Histone deacetylase 11
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3310
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q96DB2
Histone deacetylase 11
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Histone deacetylase 11 matters

As of 2026-09-14

Histone deacetylase 11 is reviewed as Histone deacetylase 11 (UniProt Q96DB2); Histone deacetylase 11 shows clinical signal disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 8 approved drugs, 1112 compounds, and 288 assays, with lead potency reaching pChEMBL 10.2.

Disease context
acute myeloid leukemia

Histone deacetylase 11 shows clinical signal disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include MOCETINOSTAT.

Start review with acute myeloid leukemia because it currently carries clinical signal support. Linked drugs include MOCETINOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 1112 compounds, and 288 assays for this target. The dominant activity type is IC50. CHEMBL2105763 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL2105763 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Histone deacetylase 11 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q96DB2, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why acute myeloid leukemia is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1112
Total Compounds
288
Total Assays
8
Approved Drugs
IC50: 1385.0, KI: 53.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2105763
 10.2 Ki Clinical
No preferred name
CHEMBL3329621
 10.0 IC50 —
No preferred name
CHEMBL3329622
 9.7 IC50 —
No preferred name
CHEMBL343448
 9.5 IC50 Approved
No preferred name
CHEMBL2105763
 9.4 IC50 Clinical

Approved Drugs

Structure Compound First Approval
GIVINOSTAT
CHEMBL1213492
 2024
PANOBINOSTAT
CHEMBL483254
 2015
BELINOSTAT
CHEMBL408513
 2014
ROMIDEPSIN
CHEMBL343448
 2009
VORINOSTAT
CHEMBL98
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:45Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3310